Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1987 1
1992 1
1993 1
1994 1
1995 1
1996 1
1998 3
1999 1
2000 7
2001 5
2002 5
2003 4
2004 5
2005 6
2006 6
2007 11
2008 15
2009 20
2010 23
2011 29
2012 25
2013 33
2014 39
2015 39
2016 37
2017 38
2018 47
2019 59
2020 66
2021 76
2022 31
Text availability
Article attribute
Article type
Publication date

Search Results

548 results
Results by year
Filters applied: . Clear all
Page 1
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL, Gill S, Ruella M. Singh N, et al. Among authors: lee yg. Nat Med. 2021 May;27(5):842-850. doi: 10.1038/s41591-021-01326-5. Epub 2021 Apr 22. Nat Med. 2021. PMID: 33888899 Free PMC article. Clinical Trial.
Erratum.
Lee YG, Jeon S, Kang SW, Park M, Baik K, Yoo HS, Chung SJ, Jeong SH, Jung JH, Lee PH, Sohn YH, Evans AC, Ye BS; Alzheimer's Disease Neuroimaging Initiative. Lee YG, et al. Alzheimers Dement (Amst). 2021 Jul 28;13(1):e12215. doi: 10.1002/dad2.12215. eCollection 2021. Alzheimers Dement (Amst). 2021. PMID: 34337131 Free PMC article.
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.
Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S, Ruella M. Singh N, et al. Among authors: lee yg. Cancer Discov. 2020 Apr;10(4):552-567. doi: 10.1158/2159-8290.CD-19-0813. Epub 2020 Jan 30. Cancer Discov. 2020. PMID: 32001516 Free PMC article.
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC. Ahn MJ, et al. Among authors: lee yg. Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3. Lancet Oncol. 2019. PMID: 31587882 Clinical Trial.
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, Cho BC. Lim SM, et al. Among authors: lee yg. J Clin Oncol. 2017 Aug 10;35(23):2613-2618. doi: 10.1200/JCO.2016.71.3701. Epub 2017 May 18. J Clin Oncol. 2017. PMID: 28520527 Clinical Trial.
548 results